The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial.

What Was Tested

This randomized controlled trial looks at Glucagon.

Although metformin is widely used for treatment of type 2 diabetes (T2D), its glucose-lowering mechanism remains unclear.

Using the glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) antagonist exendin(9-39)NH2, the researchers tested the hypothesis that postprandial GLP-1-mediated effects contribute to the glucose-lowering potential of metformin in T2D.

Who Took Part

The abstract describes 15 individuals taking part.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

The individuals were allocated by chance, so the Glucagon group and the comparison group should start out alike.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

Some individuals received a placebo instead of Glucagon, giving a reference point.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

What Was Measured

The subject headings attached to it are Metformin, Diabetes Mellitus, Type 2, Postprandial Period, Glucagon-Like Peptide 1, Blood Glucose, Hypoglycemic Agents and Peptide Fragments.

Author keywords: GLP-1, exendin(9-39)NH2, randomized controlled trial and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 15 individuals.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (European journal of endocrinology), a journal based in England.

More context: the Glucagon compound page, all human trials.